In this context, targeting LDHA holds promise in AML as it hits the Warburg effect at its core, shows a therapeutic window compared to healthy HSPCs and cannot be prevented by the presence of bone marrow stromal cells, which often protect AML cells from therapies. This evidence concerns the gene LDHA and acute myeloid leukemia.